Related Experiment Video
Updated: Jun 25, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
"A Most Equitable Drug": How the Clinical Studies of Convalescent Plasma as a Treatment for SARS-CoV-2 Might Usefully
Quinn Grundy1, Chantal Campbell1, Ridwaanah Ali1
1UNIVERSITY OF TORONTO, TORONTO, ONTARIO, CANADA.
Abstract:
Interventional clinical studies of convalescent plasma to treat COVID-19 were predominantly funded and led by public sector actors, including blood services operators. We aimed to analyze the processes of clinical studies of convalescent plasma to understand alternatives to pharmaceutical industry biopharmaceutical research and development, particularly where public sector actors play a dominant role. We conducted a qualitative, critical case study of purposively sampled prominent and impactful clinical studies of convalescent plasma during 2020-2021.
Related Concept Videos
Preclinical Development: Overview
Clinical Trials: Overview
iPS Cell Differentiation

